Is Elevation Oncology Stock a Good Investment?
Elevation Oncology Investment Advice | ELEV |
- Examine Elevation Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Elevation Oncology's leadership team and their track record. Good management can help Elevation Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Elevation Oncology's business and its evolving consumer preferences.
- Compare Elevation Oncology's performance and market position to its competitors. Analyze how Elevation Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Elevation Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Elevation Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Elevation Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Elevation Oncology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Elevation Oncology Stock
Researching Elevation Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 68.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Elevation Oncology recorded a loss per share of 0.78. The entity had not issued any dividends in recent years.
To determine if Elevation Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Elevation Oncology's research are outlined below:
| Elevation Oncology generated a negative expected return over the last 90 days | |
| Elevation Oncology has high historical volatility and very poor performance | |
| Elevation Oncology has some characteristics of a very speculative penny stock | |
| Elevation Oncology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (44.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Elevation Oncology currently holds about 122.54 M in cash with (36.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Elevation Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Elevation Oncology Plunges 42 percent on Ending Development of Lead Drug |
Elevation Oncology Quarterly Cost Of Revenue |
|
Elevation Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Elevation Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Elevation Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Elevation Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Elevation Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-02 | 2024-03-31 | -0.2 | -0.23 | -0.03 | 15 | ||
2025-03-07 | 2024-12-31 | -0.2233 | -0.18 | 0.0433 | 19 | ||
2024-03-06 | 2023-12-31 | -0.24 | -0.19 | 0.05 | 20 | ||
2023-08-03 | 2023-06-30 | -0.32 | -0.37 | -0.05 | 15 | ||
2023-11-02 | 2023-09-30 | -0.32 | -0.25 | 0.07 | 21 | ||
2024-08-06 | 2024-06-30 | -0.262 | -0.18 | 0.082 | 31 | ||
2023-05-15 | 2023-03-31 | -0.59 | -0.72 | -0.13 | 22 | ||
2021-11-12 | 2021-09-30 | -0.38 | -0.53 | -0.15 | 39 |
Know Elevation Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Elevation Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Elevation Oncology backward and forwards among themselves. Elevation Oncology's institutional investor refers to the entity that pools money to purchase Elevation Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Orbimed Advisors, Llc | 2024-12-31 | 941.3 K | Millennium Management Llc | 2024-12-31 | 815.9 K | Ikarian Capital, Llc | 2024-12-31 | 690 K | Ameriprise Financial Inc | 2024-12-31 | 444 K | Northern Trust Corp | 2024-12-31 | 432.6 K | Allostery Investments Lp | 2024-12-31 | 432.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 420.4 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 333.3 K | Citadel Advisors Llc | 2024-12-31 | 266.2 K | Tang Capital Management Llc | 2024-12-31 | 4.8 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 3.5 M |
Elevation Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.77 M.Market Cap |
|
Elevation Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.49) | (0.51) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.74) | (0.70) |
Determining Elevation Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Elevation Oncology is a good buy. For example, gross profit margin measures Elevation Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Elevation Oncology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Elevation Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elevation Oncology. Check Elevation Oncology's Beneish M Score to see the likelihood of Elevation Oncology's management manipulating its earnings.
Evaluate Elevation Oncology's management efficiency
Elevation Oncology has return on total asset (ROA) of (0.3025) % which means that it has lost $0.3025 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7748) %, meaning that it created substantial loss on money invested by shareholders. Elevation Oncology's management efficiency ratios could be used to measure how well Elevation Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.49 in 2025. Return On Capital Employed is likely to drop to -0.51 in 2025. At this time, Elevation Oncology's Intangible Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to climb to 0.000001 in 2025, whereas Total Assets are likely to drop slightly above 93.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.05 | 1.28 | |
| Tangible Book Value Per Share | 1.05 | 1.28 | |
| Enterprise Value Over EBITDA | (0.31) | (0.33) | |
| Price Book Value Ratio | 0.54 | 0.56 | |
| Enterprise Value Multiple | (0.31) | (0.33) | |
| Price Fair Value | 0.54 | 0.56 | |
| Enterprise Value | 13.9 M | 13.2 M |
Elevation Oncology benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta 1.382 |
Basic technical analysis of Elevation Stock
As of the 24th of March, Elevation Oncology shows the Standard Deviation of 8.06, variance of 64.99, and Mean Deviation of 5.06. Elevation Oncology technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Elevation Oncology mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Elevation Oncology is priced favorably, providing market reflects its regular price of 0.29 per share. As Elevation Oncology appears to be a penny stock we also advise to verify its jensen alpha numbers.Elevation Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elevation Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elevation Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Elevation Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Elevation Oncology's Outstanding Corporate Bonds
Elevation Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Elevation Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Elevation bonds can be classified according to their maturity, which is the date when Elevation Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ELV 49 08 FEB 26 Corp BondUS28622HAA95 | View | |
| ELV 475 15 FEB 33 Corp BondUS28622HAB78 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ELV 5125 15 FEB 53 Corp BondUS28622HAC51 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Elevation Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Elevation Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.52) | |||
| Mean Deviation | 5.06 | |||
| Coefficient Of Variation | (1,037) | |||
| Standard Deviation | 8.06 | |||
| Variance | 64.99 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.69) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.53) | |||
| Maximum Drawdown | 68.94 | |||
| Value At Risk | (9.43) | |||
| Potential Upside | 8.33 | |||
| Skewness | (1.39) | |||
| Kurtosis | 10.99 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.52) | |||
| Mean Deviation | 5.06 | |||
| Coefficient Of Variation | (1,037) | |||
| Standard Deviation | 8.06 | |||
| Variance | 64.99 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.69) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.53) | |||
| Maximum Drawdown | 68.94 | |||
| Value At Risk | (9.43) | |||
| Potential Upside | 8.33 | |||
| Skewness | (1.39) | |||
| Kurtosis | 10.99 |
Consider Elevation Oncology's intraday indicators
Elevation Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Elevation Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Elevation Oncology time-series forecasting models is one of many Elevation Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Elevation Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Elevation Stock media impact
Far too much social signal, news, headlines, and media speculation about Elevation Oncology that are available to investors today. That information is available publicly through Elevation media outlets and privately through word of mouth or via Elevation internal channels. However, regardless of the origin, that massive amount of Elevation data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Elevation Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Elevation Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Elevation Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Elevation Oncology alpha.
Elevation Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Elevation Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Elevation Oncology Corporate Management
| Joseph Ferra | Chief Officer | Profile | |
| Valerie MD | Chief Officer | Profile | |
| RPh PharmD | President, Founder | Profile | |
| Ryan Bloomer | Senior Operations | Profile | |
| Biren Shah | Senior Development | Profile | |
| Brian Sullivan | VP Devel | Profile | |
| Candice Masse | Senior Relations | Profile |
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.